ArticleCancer discovery2018
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 65 citations in OpenAlex.
- ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Precision therapeutic strategies for advanced gastrointestinal stromal tumors.Cancer metastasis reviews · 2026Review
- Article
- Estrogen-related receptor alpha (ERRα) promotes gastrointestinal stromal tumor progression and epithelial-mesenchymal transition through Wnt/β-catenin.Research square · 2026Article
- Counteracting FOX proteins epigenetically control the herpesvirus lytic-latent balance.Nature communications · 2026Article
- Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.Cell death discovery · 2025Review
- Modeling human gastric cancers in immunocompetent mice.Cancer biology & medicine · 2024Review
- FOXF1 promotes tumor vessel normalization and prevents lung cancer progression through FZD4.EMBO molecular medicine · 2024Article
- Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targets.NPJ precision oncology · 2024Article
- KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Cell communication and signaling : CCS · 2024Review
- A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Super-enhancers complexes zoom in transcription in cancer.Journal of experimental & clinical cancer research : CR · 2023Review
- Article
- Spontaneously evolved progenitor niches escape Yap oncogene addiction in advanced pancreatic ductal adenocarcinomas.Nature communications · 2023Article
- Cisplatin Resistance: Genetic and Epigenetic Factors Involved.Biomolecules · 2022Review
- Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumor.Cell reports · 2022Article
- HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET.Journal of experimental & clinical cancer research : CR · 2022Article
- THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.Cell communication and signaling : CCS · 2022Article
- PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.Cancer discovery · 2022Article
Corrections and comments
- Commented on by
Authors and funding
21 authors at 4 institutions in 2 countries.
Leili RanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Yuedan ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Jessica SherHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Elissa W P WongHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Devan MurphyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Jenny Q ZhangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Dan LiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Kemal DenizDepartment of Pathology, Erciyes University, Kayseri, Turkey.
Inna SirotaDepartment of Molecular Biology and Genetics, Cornell University, Ithaca, New York.
Zhen CaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Shangqian WangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Youxin GuanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Shipra ShuklaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Katie Yang LiCenter of Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Alan ChramiecCenter of Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Yuanyuan XieHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Deyou ZhengDepartment of Genetics, Albert Einstein College of Medicine, Bronx, New York.
Richard P KocheCenter of Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Cristina R AntonescuDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. chip@mskcc.org cheny1@mskcc.org.
Ping ChiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. chip@mskcc.org cheny1@mskcc.org.
Memorial Sloan Kettering Cancer Center · USAlbert Einstein College of Medicine · USCornell University · USErciyes University · TR
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MSPORE in Soft Tissue SarcomaP50CA140146 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LADANYI, MARC · 2010 to 2014
$11.1MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MAn integrative approach to target lineage-specific oncogenic transcription factorDP2CA174499 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2012 to 2012
$2.6MUnderstanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistanceR01CA208100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2017 to 2021
$2.5MPhase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)R01FD005731 · FDA · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2017 to 2020
$2.1MElucidating the roles of ETV1 in the pathogenesis of GISTK08CA151660 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2011 to 2015
$848kUnderstanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.K08CA140946 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2009 to 2013
$796kFDA HHS R01 FD005731NCI NIH HHS DP2 CA174499NCI NIH HHS K08 CA140946NCI NIH HHS K08 CA151660NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA140146NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA208100
Abstract
The cellular context that integrates upstream signaling and downstream nuclear response dictates the oncogenic behavior and shapes treatment responses in distinct cancer types. Here, we uncover that in gastrointestinal stromal tumor (GIST), the forkhead family member FOXF1 directly controls the transcription of two master regulators,
Indexed as
Gene Expression Regulation, NeoplasticGene Regulatory NetworksAnimalsBiomarkers, TumorCell CycleCell Line, TumorCell SurvivalDNA-Binding ProteinsEnhancer Elements, GeneticForkhead Transcription FactorsGastrointestinal Stromal TumorsGene Expression ProfilingHeterograftsHumansProtein BindingSignal TransductionBiomarkers, TumorDNA-Binding ProteinsETV1 protein, humanForkhead Transcription FactorsFOXF1 protein, humanTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.